Tyra Biosciences reports $86.5M net loss for 2024; cash runway through 2027; three INDs cleared

Tyra Biosciences, Inc.

Cash, equivalents, and marketable securities $341.4M at YE 2024 (up from $203.5M), providing runway through at least 2027.
Full-year 2024 net loss $86.5M vs $69.1M in 2023; R&D expenses $80.1M vs $62.5M.
TYRA-300 showed 54.5% confirmed PR (6/11) at ≥90mg QD in FGFR3+ mUC patients (SURF301).
Three INDs cleared: TYRA-300 Phase 2 for NMIBC (SURF302) and ACH (BEACH301), and TYRA-430 Phase 1 (SURF431).
First patient dosing expected Q2 2025 for BEACH301 (achondroplasia), SURF302 (NMIBC), and SURF431 (HCC).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.